Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003094 | 0.85 | DRD2 (0.39) | DRD2ADRA1ASIGMAR1EGLN1S1PR3 | |
| SCHEMBL1003096 | 0.85 | DRD2 (0.39) | DRD2ADRA1ASIGMAR1EGLN1S1PR3 | |
| SCHEMBL1002612 | 0.84 | JAK2 (0.40) | DRD2ADRA1ASIGMAR1EGLN1JAK2 | |
| SCHEMBL1003710 | 0.79 | DRD2 (0.42) | PRCPDRD2ADRA1ASIGMAR1EGLN1 | |
| SCHEMBL1003708 | 0.79 | DRD2 (0.42) | PRCPDRD2ADRA1ASIGMAR1EGLN1 | |
| Hydrochloric Acid SCHEMBL1001532 | 0.78 | JAK2 (0.40) | DRD2ADRA1ASIGMAR1EGLN1JAK2 | |
| SCHEMBL1005179 | 0.75 | DRD2 (0.43) | PRCPDRD2ADRA1ASIGMAR1EGLN1 | |
| SCHEMBL1002976 | 0.75 | DRD2 (0.38) | DRD2ADRA1AEGLN1JAK2JAK1 | |
| SCHEMBL1002977 | 0.75 | DRD2 (0.38) | DRD2ADRA1AEGLN1JAK2JAK1 | |
| SCHEMBL1003712 | 0.75 | JAK2 (0.36) | DRD2ADRA1AEGLN1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | BANYU PHARMACEUTICAL CO., INC. | 2011-01-20 | — | — | US | disclosed |
| EP-2272841-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | MC1R, MCHR2, MCHR1 | PRCP 1370/4885DRD2 164/4885ADRA1A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.